Fasenra 30 mg Injection 1 ml belongs to the class of 'immunomodulators', primarily used to treat asthma. Asthma is a chronic (long-term) respiratory condition in which airways narrow, swell, and produce extra mucus, leading to difficulty in breathing. Fasenra 30 mg Injection 1 ml is used as an add-on maintenance treatment in severe asthma patients above 12 years of age.
Fasenra 30 mg Injection 1 ml consists of Benralizumab as an active ingredient which belongs to interleukin-5 receptor (IgG1) monoclonal antibody (that serves as a substitute antibody). It works by reducing the synthesis of cytokine, a substance released by the body that initiates an inflammatory response.
Fasenra 30 mg Injection 1 ml may cause common side effects such as fever, itching, headache, sore throat, and breathing difficulty. These side effects resolve over time. Inform your doctor if any of these side effects bother you. Fasenra 30 mg Injection 1 ml will be administered by a healthcare professional. Do not self-administer
Fasenra 30 mg Injection 1 ml should be avoided if allergic to it or any other components present in it. Before starting Fasenra 30 mg Injection 1 ml, inform your doctor if you have any liver or kidney disease or active parasitic infections and are taking any inhaled corticosteroids. Pregnant and breastfeeding mothers should inform the physician before starting treatment with Fasenra 30 mg Injection 1 ml. Fasenra 30 mg Injection 1 ml may cause dizziness, so drive only if you are alert and focused. Avoid consuming alcohol along with Fasenra 30 mg Injection 1 ml as it could lead to increased dizziness.